Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash & Equivalents (2016 - 2025)

CytomX Therapeutics' Cash & Equivalents history spans 12 years, with the latest figure at $12.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 66.71% year-over-year to $12.7 million; the TTM value through Dec 2025 reached $12.7 million, down 66.71%, while the annual FY2025 figure was $12.7 million, 66.71% down from the prior year.
  • Cash & Equivalents reached $12.7 million in Q4 2025 per CTMX's latest filing, down from $34.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $329.7 million in Q1 2021 to a low of $12.7 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $103.4 million, with a median of $52.7 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 130.08% in 2021, then plummeted 91.13% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $205.5 million in 2021, then decreased by 5.78% to $193.6 million in 2022, then tumbled by 91.13% to $17.2 million in 2023, then surged by 121.61% to $38.1 million in 2024, then plummeted by 66.71% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Cash & Equivalents are $12.7 million (Q4 2025), $34.2 million (Q3 2025), and $49.0 million (Q2 2025).